EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios

Wei Zhang, Song Li iD, Tianming Yan iD, Congjun Zhou, Xinyi Lei, Cairong Zhu iD

Vaccines · 01.07.2026 · 14 (7) · 587

DOI: 10.3390/vaccines14070587 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 01.07.2026. Verfasst von Wei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 6100…. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim was to evaluate the cost-effectiveness of self-paid vaccination using Zoster Vaccine Live (ZVL) and Recombinant Zoster Vaccine (RZV) in China, as well as their inclusion in China’s National Immunization Program (NIP), and to determine the most cost-effective initial vaccination age under this inclusion strategy.

Methods

Based on the ZONA model, a Markov model was developed by incorporating pain severity levels for herpes zoster (HZ) and postherpetic neuralgia (PHN), allowing for dynamic transitions between health states. The model evaluated the cost-effectiveness of six vaccination strategies from a societal perspective. Economic evaluations were conducted using the incremental cost-effectiveness ratio (ICER), quality-adjusted life-years (QALYs), and incremental cost-utility ratio (ICUR). The robustness of the results was verified through sensitivity analysis.

Results

In the self-paid scenario, both RZV and ZVL were economically viable for preventing HZ. However, neither was cost-effective in preventing PHN. When included in the NIP, initiating RZV vaccination at age 50 demonstrated dominance (higher quality-adjusted life years and lower costs), with an ICER of −3826 CNY per HZ case prevented, −38,669 CNY per PHN case prevented, and an ICUR of −11,128 CNY per QALY gained. Subgroup analysis indicated that initiating RZV vaccination at age 50 offered the best cost-effectiveness, while age 70 was the most cost-saving option.

Conclusions

Generally, RZV demonstrates greater cost-effectiveness compared to ZVL. Incorporating RZV into the NIP, starting at age 70, is the optimal strategy to reduce the burden of HZ and PHN and improve healthcare resource allocation in China.

Schlagwörter

Stichwörter der Autor:innen

Markov modelPHNcost-effectivenessherpes zoster

Autor:innen und Institutionen

  • Department of Epidemiology and Health Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China.

ORCID-Profile: Song Li, Tianming Yan, Cairong Zhu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Li, S., Yan, T., Zhou, C., Lei, X., & Zhu, C. (2026). Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios. Vaccines, 14(7), 587. https://doi.org/10.3390/vaccines14070587

Vancouver

Zhang W, Li S, Yan T, Zhou C, Lei X, Zhu C. Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios. Vaccines. 2026;14(7):587. doi:10.3390/vaccines14070587

BibTeX
@article{Zhang2026,
  author = {Zhang, Wei and Li, Song and Yan, Tianming and Zhou, Congjun and Lei, Xinyi and Zhu, Cairong},
  title = {Cost-Effectiveness of Recombinant Versus Live-Attenuated Herpes Zoster Vaccination in China: A Modeling Study Under Self-Paid and National Immunization Scenarios},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {7},
  pages = {587},
  doi = {10.3390/vaccines14070587}
}
Kostenlos starten →